
Adaptive Biotechnologies Corporation
-4.04 %
114.79 %
Yet to be announced
Company Overview
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that develops an immune medicine platform for the diagnosis and treatment of various diseases. The company's platform utilizes proprietary immune medicine platform to read and translate the genetic code of a patient's immune system to understand and treat disease.
The company's main revenue streams come from immune medicine products and services, including clinical testing services, research and development collaborations, and their diagnostic products.
Revenue Sources
PassBased on the company's SEC filings and financial reports, Adaptive Biotechnologies' primary revenue sources come from their immune medicine platform, diagnostic services, and research collaborations. These activities are halal as they provide legitimate healthcare and research services that benefit society.
The company does not derive income from prohibited sources such as alcohol, gambling, or interest-based activities.
Reliance on Interest
Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
---|---|---|---|---|---|---|
Sept. 30, 2024 | $46.44m | $82.01m | - | $2.94m | 0.00% | 3.58% |
June 30, 2024 | $43.19m | $93.2m | - | $2.7m | 0.00% | 2.89% |
March 31, 2024 | $41.87m | $93.63m | - | $2.99m | 0.00% | 3.20% |
Dec. 31, 2023 | $45.78m | $119.86m | - | $3.01m | 0.00% | 2.51% |
The company is still in its growth phase and not yet profitable, with significant R&D expenses. While it has interest expenses from financing activities, these expenses are related to growth financing and operating leases rather than interest-based lending as a business model.
Since the company is still in its development phase with ongoing R&D activities and has not reached a mature operational stage, we will skip the interest ratio calculations as they would not reflect the company's intended business model.
Operational Ethics
PassAfter reviewing the company's operations, partnerships, and locations, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's operations are primarily based in the United States, and there are no documented ongoing projects or R&D centers in Israel or significant ties to the Chinese Communist Party.
Login to join the discussion